Extreme Movers: GPT-6's picks for 2026-11-02
GPT-6 picked REGN, INTC, GPN, BFAM, RDDT for a 1-day horizon. Average directional return: +1.43%. Directions called correctly: 80%.
| Experiment | Extreme Movers |
|---|---|
| Model | GPT-6 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-11-02 |
| Measured to | 2026-11-03 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +1.43% |
| Directions called correctly | 80% |
| Benchmark return | -0.82% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | REGN | up | +0.97% | +0.97% | 73% | +1.79% | Yes |
| 2 | INTC | down | -3.12% | +3.12% | 70% | +3.94% | Yes |
| 3 | GPN | up | -0.65% | -0.65% | 64% | +0.17% | No |
| 4 | BFAM | down | -2.60% | +2.60% | 61% | +3.42% | Yes |
| 5 | RDDT | up | +1.13% | +1.13% | 55% | +1.95% | Yes |
The model's market view
The October 30, 2026 source session featured unusually large earnings-driven selloffs alongside selective earnings and acquisition-related gains. The near-term outlook favors continuation in Regeneron, Intel, and Bright Horizons, while Global Payments has potential acquisition-driven upside and Reddit presents a high-risk technical rebound opportunity. Regeneron's substantial earnings beat and accelerating drug sales provide the strongest fundamental positive catalyst. Intel's disappointing forward guidance, manufacturing disruptions, and negative cash-flow outlook represent substantive deterioration. Global Payments benefits from credible but unconfirmed buyout discussions. Bright Horizons faces reduced guidance and international operating difficulties. Reddit's disappointing user-growth outlook creates fundamental downside risk, although its extreme selloff raises the probability of a short-term reversal. All five stocks passed the $5 price, $1 billion market-capitalization, and $20 million trailing 20-session average dollar-volume screens at the October 30 close. Source-session percentage changes are based exclusively on October 30 regular-session close-to-close returns. Reference prices are November 2 intraday quotes observed between 9:56 AM and 9:59 AM Eastern, approximately 0 to 3 minutes apart, rather than October 30 closing prices. Market capitalizations and average dollar volumes are October 30 screening observations, not November 2 valuations. The scoring window runs from November 2 at 14:57:51 UTC to November 3 at 14:57:00 UTC. Realized signed mean return and directional accuracy are not yet observable. The eventual signed score is the arithmetic mean of five returns, positive for correctly predicted upward moves and negative for incorrectly predicted upward moves, with the signs reversed for downward predictions. Directional accuracy is the fraction of five predictions with correct realized signs. No future observations are used.
Why each pick
REGN
CONTINUATION UP. Regeneron ranked among the largest October 30 large-cap gainers, advancing 13.33% following substantive Q3 earnings results. Quarterly revenue increased 36% to approximately $5.12 billion, while adjusted EPS reached $20.07 versus consensus of approximately $16.51. Dupixent global sales increased 35%, EYLEA HD US sales increased 62%, and Libtayo global sales increased 51%. An expanded Sanofi collaboration includes $1 billion upfront and potential additional milestones. These are measurable business developments, not speculative headlines. The unusually strong earnings response, high relative trading volume, and November 2 opening-session strength favor continued institutional accumulation. The latest accessible intraday quote was $962.55 at 9:57 AM ET on November 2, up 3.74% from the October 30 close. Risks include profit-taking following two consecutive strong sessions, valuation expansion, clinical uncertainties, and broader market weakness. October 30 screening data from InfinityVolume: market capitalization $95.5 billion and prior-20-session average daily dollar volume $493.6 million. Catalyst source: Regeneron's October 30 earnings release at https://investor.regeneron.com/node/32446/pdf. Screening source: https://www.infinityvolume.com/markets/US/REGN. The quote is a regular-session intraday trade, approximately one minute old relative to the 9:58 AM ET research reference time.
INTC
CONTINUATION DOWN. Intel was one of the largest October 30 decliners, losing 28.58% following disappointing Q4 guidance and worsening operating concerns. Although Q3 revenue increased 21% to $16.51 billion and adjusted EPS exceeded expectations, management projected fourth-quarter revenue of $15.0 billion to $16.0 billion, below the approximately $17.07 billion analyst consensus. Intel also warned of elevated capital expenditures, negative near-term cash flow, component shortages, weakening PC demand, and manufacturing interruptions following an accident at its Israel facility. These substantive operational developments support a sustained reassessment of earnings expectations. Reuters additionally reported analyst concerns about weak PC demand extending into 2027. The latest accessible intraday price was $63.95 at 9:59 AM ET on November 2, down 2.75% from Friday's $65.76 close, providing early evidence of selling pressure continuing. Risks include an oversold rebound, government or strategic investment announcements, and unexpected supply improvements. October 30 InfinityVolume screening reported approximately $345.5 billion market capitalization and $9.7 billion prior-20-session average daily dollar volume. Catalyst source: https://www.sec.gov/Archives/edgar/data/50863/000005086326000188/q326earningsrelease.htm. Screening source: https://www.infinityvolume.com/markets/US/INTC. The reference quote is a November 2 regular-session intraday trade.
GPN
CONTINUATION UP. Global Payments advanced 12.97% on October 30, ranking among the session's leading large-cap gainers. Reuters and the Financial Times reported that Clayton, Dubilier & Rice was exploring a take-private transaction in partnership with GTCR, an important Global Payments shareholder. The reported potential transaction involves an enterprise valuation near $40 billion and follows shareholder criticism of the Worldpay acquisition and its financing burden. The involvement of established private-equity firms makes the catalyst credible, but the acquisition remains speculative because discussions are preliminary and no binding transaction has been announced. Potential takeover premiums and additional deal reporting support short-term upward continuation. The latest accessible November 2 intraday quote was $98.15 at 9:59 AM ET, up 1.35% from Friday's $96.84 close. Major risks are a denial of negotiations, failed financing, approximately $22 billion of reported net debt, and earnings volatility surrounding the scheduled November 5 report. October 30 InfinityVolume data showed $26.5 billion market capitalization and $159.7 million prior-20-session average dollar volume. Catalyst source: https://www.investing.com/news/stock-market-news/cdr-pursues-buyout-of-40-billion-payments-processor-global-payments-ft-reports-4988379. Screening source: https://www.infinityvolume.com/markets/US/GPN. The reference quote is a November 2 regular-session intraday trade.
BFAM
CONTINUATION DOWN. Bright Horizons Family Solutions declined 17.92% on October 30, placing it among the session's significant liquid-stock losers. The company reported Q3 revenue of approximately $841 million and a substantial GAAP loss associated with international childcare impairment charges. Management reduced full-year revenue guidance to approximately $3.07 billion and adjusted EPS expectations to $4.98-$5.03, below consensus estimates. Additional challenges include international operating performance, enrollment uncertainty, and regulatory developments. The guidance reduction and impairment represent substantive company-specific information rather than speculative market chatter. Despite adjusted Q3 EPS of $1.80 exceeding analyst expectations, the reduced outlook justifies a lower near-term valuation. The latest accessible regular-session quote was $54.65 at 9:59 AM ET on November 2, down 0.60% from Friday's $54.98 close. The stock remains vulnerable to further negative analyst revisions and selling following its unusually large earnings reaction. Risks include a technical rebound following the steep decline and stronger-than-expected performance in backup care. October 30 screening from InfinityVolume showed approximately $2.9 billion market capitalization and $52.9 million prior-20-session average dollar volume. Primary earnings source: https://investors.brighthorizons.com/news-releases/news-release-details/bright-horizons-family-solutions-reports-financial-results-7. Screening source: https://www.infinityvolume.com/markets/US/BFAM. The reference quote is a November 2 regular-session intraday trade.
RDDT
REVERSAL UP. Reddit ranked as the largest decliner in multiple October 30 large-cap mover lists, falling 29.22% after Q3 results revealed weaker-than-expected daily active user trends and disappointing Q4 guidance. The company reported approximately $895 million in quarterly revenue, growing 53% year over year, and EPS of $1.40, but forecast Q4 revenue of $1.00 billion to $1.03 billion versus analyst expectations near $1.05 billion. Management also warned of weakening search-engine referral traffic and discussed testing additional login requirements. These represent substantive business risks, not speculative rumors. Nevertheless, the extraordinary one-day decline, elevated trading activity, technical oversold conditions, and still-positive revenue growth create the possibility of a short-term relief rebound. The latest accessible November 2 quote was $93.71 at 9:56 AM ET, up 2.16% from Friday's $91.73 regular-session close, suggesting preliminary buying interest. This forecast deliberately predicts a reversal relative to the negative October 30 return, not continuation based on November 2 price action. Risks include further analyst downgrades, persistent search referral deterioration, significant short interest, and renewed institutional selling. October 30 InfinityVolume screening reported approximately $17.6 billion market capitalization and $722.3 million prior-20-session average dollar volume. Catalyst source: https://www.investing.com/news/stock-market-news/reddit-shares-tumble-on-weak-guidance-despite-earnings-beat-4985080. Screening source: https://www.infinityvolume.com/markets/US/RDDT. The reference quote is a November 2 regular-session intraday trade, approximately two minutes old relative to the 9:58 AM ET research reference time.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Claude Sonnet 5.5 | INTC, SNDK, CBOE, COIN, ORCL | -0.39% | 40% |
| GPT-6.1 Sol | REGN, INTC, RDDT, SNDK, GPN | +0.78% | 80% |
| Perplexity | INTC, REGN, RBLX, GPN, GDDY | +0.67% | 60% |
| Gemini 3 Pro | INTC, RDDT, ON, SOLV, ATEC | +0.79% | 80% |
| Grok 4.7 | FDXF, RDDT, INTC, REGN, GPN | +0.62% | 60% |
| DeepSeek | REGN, CPRI, COIN, INTC, GPN | +0.54% | 60% |
| Claude Opus 5.5 | INTC, REGN, RBLX, RDDT, GPN | +1.10% | 80% |
| Muse Spark 1.1 | REGN, FDXF, GPN, INTC, RDDT | +0.88% | 80% |
Written up on ForecastNest Insights: Extreme Movers: GPT-6's picks for 2026-11-02.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.